Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.
about
Infections and inflammation in prostate cancerSerum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control studyProspective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.Human papillomavirus 16 infection as a potential risk factor for prostate cancer: an adaptive meta-analysis.Metachronous anal canal and prostate cancers with simultaneous definitive therapy: a case report and review of the literature.Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysisAge-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global reviewCharacterisation of microbial communities within aggressive prostate cancer tissuesSexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses.Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: the best and the worst.Role of antibodies to human papillomavirus 16 in prostate cancer: A seroscreening by peptide microarray.Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.Is human papillomavirus associated with prostate cancer survival?Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients.-ΔG is associated with prostate cancer among men at increased risk of sexually transmitted infections
P2860
Q28652733-84EE378F-C9C5-43B5-844D-B0BC01D45B4CQ33811238-5F46D8DF-2C0D-454C-8D75-86186A3DEF60Q34810223-345FE606-1CD3-4D2A-BA6C-6B633040B96EQ35211033-1C6EB94C-F576-4105-B439-081B668DBE2CQ35952725-7ABD5B1A-5941-43A5-BDDF-7033B84BE393Q36123728-CADD0047-8191-4C8B-89F2-47828C7FB366Q36609068-2870ECAA-61D0-40A9-B7C3-810BE7DBE4D1Q37586899-336DC506-C326-4B1F-B650-45E94E4F5BEFQ37783620-89691D5A-0A4D-4D05-B3F7-CDE5DAEC2E42Q38023979-9FAD619E-7539-4BCA-B90B-34C326C9910BQ40158558-440B06AE-A7F5-430A-ABB8-8D75C9AB5703Q41742178-6E73C4E2-B5E2-46F0-A252-3ED752A4546CQ42252288-6ED12DE9-4B75-4B01-9FD2-F5ECD0474BF3Q43736737-EC706835-B811-4EE3-AF3C-26E68B66D5F3Q59136722-D2F6D9DE-4488-449D-A9E7-3E2A29CEACF5
P2860
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Human papillomavirus types 16, ...... state Cancer Prevention Trial.
@ast
Human papillomavirus types 16, ...... state Cancer Prevention Trial.
@en
type
label
Human papillomavirus types 16, ...... state Cancer Prevention Trial.
@ast
Human papillomavirus types 16, ...... state Cancer Prevention Trial.
@en
prefLabel
Human papillomavirus types 16, ...... state Cancer Prevention Trial.
@ast
Human papillomavirus types 16, ...... state Cancer Prevention Trial.
@en
P2093
P2860
P1476
Human papillomavirus types 16, ...... ostate Cancer Prevention Trial
@en
P2093
Angelo M De Marzo
Ann W Hsing
Ashraful M Hoque
Cathee Till
Elizabeth A Platz
Ian M Thompson
Jonathan M Zenilman
Phyllis J Goodman
Raphael P Viscidi
P2860
P304
P356
10.1158/1055-9965.EPI-09-1080
P577
2010-02-01T00:00:00Z